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Abstract
Background: Suspicious pigmented lesions are a common presenting problem in general practice consultations; 
while the majority are benign a small minority are melanomas. Differentiating melanomas from other pigmented 
lesions in primary care is challenging: currently, 95% of all lesions referred to a UK specialist are benign. The MoleMate 
system is a new diagnostic aid, incorporating a hand-held SIAscopy scanner with a primary care diagnostic algorithm. 
This trial tests the hypothesis that adding the MoleMate system to current best primary care practice will increase the 
proportion of appropriate referrals of suspicious pigmented lesions to secondary care compared with current best 
practice alone.
Methods/design: The MoleMate UK Trial is a primary care based multi-centre randomised controlled trial, with 
randomisation at patient level using a validated block randomisation method for two age groups (45 years and under; 
46 years and over). We aim to recruit adult patients seen in general practice with a pigmented skin lesion that cannot 
immediately be diagnosed as benign and the patient reassured. The trial has a 'two parallel groups' design, comparing 
'best practice' with 'best practice' plus the MoleMate system in the intervention group. The primary outcome is the 
positive predictive value (PPV) of referral defined as the proportion of referred lesions seen by secondary care experts 
that are considered 'clinically significant' (i.e. biopsied or monitored). Secondary outcomes include: the sensitivity, 
specificity and negative predictive value (NPV) of the decision not to refer; clinical outcomes (melanoma thickness, 5 
year melanoma incidence and mortality); clinician outcomes (Index of Suspicion, confidence, learning effects); patient 
outcomes (satisfaction, general and cancer-specific worry), and cost-utility.
Discussion: The MoleMate UK Trial tests a new technology designed to improve the management of suspicious 
pigmented lesions in primary care. If effective, the MoleMate system could reduce the burden on skin cancer clinics of 
patients with benign pigmented skin lesions, and improve patient care in general practice.
Background
1.1 Melanoma and health policy
Suspicious pigmented lesions (SPLs), or 'moles' are a
common presenting problem in general practice consul-
tations, and while the majority are benign, a small minor-
ity are malignant melanomas. Melanoma is a serious skin
cancer, accounting for less than one in ten skin cancers,
but responsible for 2% of all cancers and 1% of all cancer
deaths in the UK, with around 9,500 new cases and 1,800
deaths a year (Cancer Research UK). Worldwide, the inci-
dence of melanoma is increasing faster than any other
cancer, with an approximate doubling of rates every 10-
20 years in countries with white populations [1]. While
the incidence in the UK is one of the highest in Europe, it
is lower than the reported incidence from other countries
such as Australia and New Zealand, which lead the world
age-standardised rates at about 50 per 100,000 popula-
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tion per annum [2] (compared with 11.9 per 100,000 pop-
ulation in the UK (Cancer Research UK)). Furthermore,
although the incidence of melanoma increases with age, a
third of all cases occur in people aged less than fifty years
and it is the second most common cancer in the 20-39
age group. The increasing incidence has been attributed
to increases in ultra-violet exposure, both natural and
artificial. Other risk factors include genetic predisposi-
tion reflected in the phenotypic features of multiple
moles, fair complexion, sunburn-susceptible skin types,
and family history. In the UK, melanomas are more com-
mon in women than in men, although the prognosis is
poorer for men over 60 years who tend to present with
thicker melanomas [3].
Early detection is critical in reducing mortality and
morbidity from melanoma, as thin lesions (Breslow thick-
ness less than 1 mm) have a five-year survival of over
95%, compared to less than 50% for thicker lesions
(Breslow thickness more than 4 mm). There is evidence
from the UK that expert consultation within 2 weeks of
referral results in thinner tumours and improved overall
survival [4]. The Department of Health's recent Cancer
Reform strategy highlighted the issues of poor public
awareness of cancer symptoms, diagnostic delays in pri-
mary care and late diagnosis across all cancers. In
response, the National Awareness and Early Diagnosis
Initiative was jointly launched by Cancer Research UK
and the Department of Health in 2008 [5] with two of the
seven key objectives being to develop interventions to
promote early presentation and reduce diagnostic delays
in primary care.
1.2 Primary care management of suspicious pigmented 
lesions
While some patients present late, the vast majority who
present to their general practitioners (GPs) with concerns
about moles or other pigmented skin lesions, will not be
diagnosed with melanoma: even among men aged over 60
years, less than 1 in 33,000 moles are estimated to
become malignant [6]. GPs need to be able to reassure
those with benign lesions and rapidly refer those with
suspicious lesions. This is a difficult challenge and, when
compared with dermatologists, GPs can be highly sensi-
tive but less specific for the diagnosis of melanoma [7,8]:
consequently, the majority of lesions referred to skin can-
cer clinics in the UK prove to be benign [9]. Referral or
d i a g n o s t i c  e f f i c i e n cy  c a n  b e  m e a s u r e d  i n  t e r m s  o f  t h e
ratio of benign to malignant lesions, or the proportion of
referred lesions that are malignant. In 2003, the UK All
Party Parliamentary Group on Skin reported that up to
nineteen out of every twenty lesions referred to a derma-
tologist by a GP under the two-week cancer standard
w e r e  b e n i g n .  A n  e v a l u a t i o n  o f  E n g l a n d ' s  2 - w e e k  w a i t
referrals showed that melanomas and squamous cell car-
cinomas accounted for 10 - 12%, with the remainder
found to be benign lesions [10].
In an attempt to maximise sensitivity and specificity of
melanoma diagnosis by GPs and their referral efficiency,
a variety of educational, checklist and technical
approaches have been developed. There is equivocal evi-
dence about the usefulness of training courses: while ran-
domised controlled trial evidence from the US suggests
some benefit from face-to-face [11] and internet [12]
training, Australian studies have shown that face-to-face
training of GPs in melanoma diagnosis has no significant
effect on their performance [7]. The ABCD [13] and
seven-point [14] checklists have been widely evaluated
and revised, but each has significant drawbacks in help-
ing GPs distinguish between benign pigmented lesions
and melanomas [15]. Technical approaches include the
use of dermoscopy, laser microscopy, ultrasonography
and magnetic resonance imaging [16]. A recent trial of
dermoscopy and digital monitoring in Australian general
practice found that the combination of these techniques
can increase the sensitivity of GPs for the diagnosis of
melanoma, and significantly reduce the proportion of
benign lesions excised [17]. However, learning these tech-
niques took considerable time and was completed by only
62% of trial GPs. Therefore, other approaches that are
easier to learn are still required to improve GPs' diagnos-
tic performance and support the assessment of pig-
mented skin lesions in primary care.
1.3 SIAscopy and the MoleMate system
SIAscopy is an innovative technology that uses a non-
invasive multispectral scanning technique to produce
images of the light-absorbing chromaphores haemoglo-
bin, melanin and collagen, in the epidermis and papillary
dermis. Patterns within the SIAscans of pigmented skin
lesions have been shown to indicate histopathological
and pathophysiological features consistent with mela-
noma, and, in combinations, these features were highly
sensitive (83%) and specific (80%) for melanoma in the
experimental setting [18]. The Moncrieff Scoring System
was developed and, in a population referred to a skin can-
cer clinic, was shown to have 94.4% sensitivity and a 3.7%
false positive rate for melanoma [19]. In the primary care
setting the Moncrieff Scoring System was less sensitive
for the diagnosis of 'suspicious' lesions (54.2%) and mela-
noma (66.7%), and a new Primary Care Scoring Algo-
rithm (PCSA) was developed to account for the higher
prevalence of seborrhoeic keratoses and haemangiomas
seen in primary care. This had a similar sensitivity for the
diagnosis of 'suspicious' (50.0%) but was more specific
(84.2%). Based on simulation modelling, the PCSA also
demonstrated high sensitivity and specificity for the diag-
nosis of melanoma (94.0% and 83.5% respectively)
[20,21].Walter et al. BMC Family Practice 2010, 11:36
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Subsequently the PCSA was incorporated into the
MoleMate system. This randomised controlled trial
(RCT), set in UK general practice, aims to test the
hypothesis that use of the MoleMate system will improve
the management of suspicious pigmented lesions in pri-
mary care compared with current best practice, and that
this will be reflected in the appropriateness of referrals to
skin cancer clinics.
Methods/designs
2.1 Definitions
For the purpose of this trial, the definition of 'suspicious
pigmented lesion' is any lesion presented by a patient, or
opportunistically seen by a clinician in general practice,
which cannot immediately be diagnosed as benign and
the patient reassured.
The definition of 'appropriateness of referral' is whether
the referred lesion is deemed 'clinically significant' by a
dermatologist in a skin cancer clinic and is therefore
either biopsied or monitored. Those lesions seen by a
dermatologist in a skin cancer clinic which result in reas-
surance and discharge from the clinic without biopsy or
monitoring are deemed 'clinically insignificant'.
2.2 Sponsorship and ethical approval
The trial is jointly sponsored by the University of Cam-
bridge and Cambridgeshire Primary Care Trust (now
renamed NHS Cambridgeshire). Cambridgeshire 2
Research Ethics Committee has reviewed and approved
the protocol (07/H0308/167).
2.3 Trial design and randomisation
This randomised controlled trial comprises 2 stages: a
pilot phase and the main trial. The pilot phase was con-
ducted in 3 general practices over a 4-month period; dur-
ing this time the study procedures were refined and
projected recruitment rates confirmed. The study design
and flow of participants through the trial are shown in
Figure 1. Once eligible patients have been internally
referred within the general practice to one of the trial
Lead Clinicians and recruited into the trial, participants
are randomised to either the comparison ('best practice')
group or the intervention (MoleMate system) group. Par-
ticipants are randomised using a block randomisation
method with sets of numbered, sealed envelopes pre-
pared by the trial statistician (ATP), with the order of the
sequences used being verified afterwards. Randomisation
is stratified by age (45 years and under; 46 years and over)
and by Lead Clinician.
2.4 Setting
Fifteen general practices are participating in the trial:
thirteen in Cambridgeshire, one in West Essex and one in
Suffolk. Practices already using a MoleMate system have
been excluded. Two Lead Clinicians per practice have
undergone training in the use and interpretation of the
MoleMate system, and in all study procedures. GPs with
known dermatological expertise eg GPs with a special
interest (GPSI), Hospital Practitioners and Clinical Assis-
tants in Dermatology, were excluded from being Lead
Clinicians.
2.5 Patients
Patients are eligible for the trial if aged 18 years or over,
able to give informed consent, and have a pigmented
lesion (either presented by the patient or noticed by a
health care professional) which is not immediately diag-
nosed as benign and the patient reassured. These patients
are given an appointment with a Lead Clinician within
one week and provided with information about the Mole-
Mate Trial prior to formal consent and recruitment by
the Lead Clinician.
2.6 Study procedures
At the trial consultation, the Lead Clinician consents and
randomises the patient into the 'comparison' or 'interven-
tion' group.
Comparison group
Participants in the comparison group have their lesion
assessed in the usual 'best practice' manner using the
clinical history, naked eye examination and the seven-
point checklist [14].
Intervention group
Prior to commencing patient recruitment, Lead Clini-
cians complete a MoleMate Training CD-rom which
teaches users to identify relevant SIAscopic features of
various pigmented skin lesions. The Training CD-rom
takes up to 2 hours to complete and has been shown to
significantly improve GPs' ability to interpret SIAscopic
images [22]. Participants in the intervention arm have
their lesion/s assessed according to the same 'best prac-
tice' principles in the comparison arm. Lead Clinicians
then use the MoleMate system to support their assess-
ment and management of the lesion.
For all lesions an Index of Suspicion scale is completed,
and the clinical diagnosis and intended action recorded
(suspicious and refer via the two-week cancer route, or
benign and reassure). A digital photograph is taken of
every lesion for expert review.
2.7 Reference standards
Although the true 'gold standard' would be histology on
all lesions, this would not be practical or ethically accept-
able for every participant. In clinical practice, an expert
opinion is considered the practical 'standard' of whether
or not a pigmented lesion is 'clinically significant' in
requiring monitoring or biopsy.
2.7.1 Referred lesions
All lesions considered 'suspicious' by a Lead Clinician
from both trial arms are referred to secondary careWalter et al. BMC Family Practice 2010, 11:36
http://www.biomedcentral.com/1471-2296/11/36
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Figure 1 Trial flowchart.

Approx. 
Timescale  
1 week 
maximum 
3 weeks 
maximum 
3 months 
6 months 
6.5 months 
Informed consent & participant randomisation
Appointment with Practice Clinician 
Pigmented skin lesion, which cannot immediately be reassured as benign. 
Patient referred to Practice Lead Clinician for Trial appointment within 1 week 
Trial Appointment with Lead Clinician  
Intervention group 
Lesion assessment & digital photograph  
Assessment using the MoleMate system 
Clinical decision: suspicious or not suspicious 
Control group 
Lesion assessment & digital photograph  
Clinical decision: suspicious or not suspicious
Clinical decision: suspicious.
Referred to dermatology within 2 weeks 
Clinical decision: not suspicious.
Participant reassured, then followed up in primary care 
Appointment in Dermatology 
Diagnosis recorded  
Not clinically significant (follow-up through Cancer 
Registry) 
or  
Clinically significant (monitored or biopsied)
Second questionnaire mailed to participant  Second questionnaire mailed to participant 
Audit Appointment with Lead Clinician  
Lesion re-assessment & digital photograph  
Clinical decision: suspicious or not suspicious
Clinical decision: suspicious 
Referred to dermatology within 
2 weeks 
Clinical decision: not suspicious
Participant reassured. 
Follow-up through Cancer 
Registry 
Appointment in Dermatology 
Diagnosis recorded  
Not clinically significant (follow-up through Cancer 
Registry) 
or  
Clinically significant (monitored or biopsied)Walter et al. BMC Family Practice 2010, 11:36
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(Addenbrooke's Hospital) via the normal two-week skin
cancer care pathway, where one of three dermatologists
(Experts A, B and C) provide an opinion as to whether or
not the pigmented lesion is 'clinically significant'.
2.7.2 Non-referred lesions
All lesions considered 'not suspicious' by a Lead Clinician,
and therefore not referred, are assessed three months
later by two other skin cancer experts (Experts D and E).
The expert assessment includes review of the seven-point
checklist, the digital photograph and, for intervention
group participants, the MoleMate images to make the
final reference standard diagnosis of 'suspicious' or 'not
suspicious'.
2.8 Safety procedures
All non-referred participants with a lesion considered
'suspicious' by Experts D and E are invited to an early
review by the Lead Clinician to re-assess the lesion and
thus ensure safety in the study. All other participants with
'not suspicious' lesions, as determined by Experts D and
E, are invited to attend an Audit Appointment with the
Lead Clinician six months after their first consultation. At
this consultation the lesion is re-examined and the seven-
point checklist and digital photograph repeated. Experts
D and E compare these new data with the original trial
data to ensure no potentially suspicious lesions are
'missed' within the trial. This safety-net procedure was
introduced in response to concerns raised by the
Research Ethics Committee.
2.9 Measurement
Table 1 summarises the content and timing of all the clin-
ical and psychological measures.
2.9.1 Primary outcome
The primary outcome is the positive predictive value
(PPV) of the primary care decision to refer. This is
defined as the proportion of referred lesions that are con-
sidered 'clinically significant' (biopsy or monitor) by sec-
ondary care experts, and is therefore the proportion of all
referred lesions that are deemed 'clinically significant'.
This is a measure of the appropriateness of a referral and,
by implication, the diagnostic accuracy of the GP with or
without the aid of the MoleMate system.
2.9.2 Secondary outcomes
Related to the primary outcome - Volume of referrals:
there is a possibility that the proportion of appropriate
referrals will be the same in the Intervention and Com-
parison groups despite differences between these groups
in the number of total referrals (denominator) and the
number of clinically significant lesions (numerator). The
primary outcome measure will be unpacked to examine
the total number of referrals (i.e. volume) and the number
of clinically significant lesions in each group;
- Sensitivity, specificity and negative predictive value
(NPV) of the decision not to refer using data from all
lesions in the trial.
Clinical outcomes - Thickness of melanomas biopsied in
secondary care clinics;
- 5 year melanoma incidence and mortality among trial
participants collected through the Eastern Cancer Regis-
tration and Information Centre (ECRIC).
Table 1: Trial measures and timing.
Time after 1st Lead Clinician (LC) consultation
All participants Non-referred 
participants
Referred 
participants
1st LC
consultation
up to 1
week
3 months 6 months within 2
weeks
Clinical assessment of lesion(s) √√ √
Psychological measures (questionnaire)
Anxiety: short form STAI† √√
Cancer worry: modified cancer worry scale √ √
Satisfaction with LC consultation¥ √
† Spielberger State-Trait Anxiety Inventory
¥ Items from Europep instrument relating to the dimensions of careWalter et al. BMC Family Practice 2010, 11:36
http://www.biomedcentral.com/1471-2296/11/36
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Clinician outcomes - Accuracy of Index of Suspicion
scale;
- Confidence and attitudes of Lead Clinicians towards
the MoleMate intervention will be assessed 2 weeks after
trial set-up and at trial completion using a modified mea-
sure based on the Theory of Planned Behaviour [23];
-  L e a r n i n g  e f f e c t s :  i t  i s  p o s s i b l e  t h a t  t h e  M o l e M a t e
training programme, and using the MoleMate system in
practice, may improve the Lead Clinicians' accuracy to
assess pigmented lesions clinically and thereby affect
management of lesions in both groups. We will therefore
examine potential contamination effects by comparing
the appropriateness and volume of referral between
groups for the first ten MoleMate consultations of each
L e a d  C l i n i c i a n ' s  d a t a  c o l l e c t i o n  w h e n  c o n t a m i n a t i o n
would be minimal ('naive period'), with the remaining
consultations ('potentially contaminated period').
Patient outcomes Participants will complete the follow-
ing psychological measures within 1 week and at 3
months after their consultation with the Lead Clinician:
- General and cancer-specific worry: Anxiety using the
Spielberger State-Trait Anxiety Inventory, STAI [24] and
a modified cancer worry scale [25];
- Satisfaction with the trial consultation using dimen-
sions of care items from Europep [26].
Resource use and costs The cost of the MoleMate sys-
tem to the NHS will be assessed using the following data:
costs of the MoleMate system (purchase, maintenance
and technical support, staff training), costs of primary
care activity (initial and diagnostic GP visits), and costs of
secondary care activity (referrals, excision).
2.10 Sample size
Our pilot study confirmed projected recruitment rates
(6-8 participants per practice per month) and referral
rates (approximately 2 referrals per practice per month).
Based on these, to detect an increased biopsy rate of 10%
amongst those referred of 22% ('intervention' group) ver-
sus 12% ('comparison' group), an odds ratio of 2.0, with
80% power at the 5% significance level, would require 442
analysed in the primary outcome sample of referred
lesions. With the involvement of 15 practices, this would
require 30 referred lesions per practice. Assuming a 25%
referral rate this could be achieved by randomising 120
patients per practice (1800 total) with an assumed
recruitment rate of 90 per year over a 16-month period.
A blinded interim analysis, presented at the Trial Steer-
ing Committee meeting half-way through the study (Sep-
tember 2009) after 747 participants had been
randomised, established a lesion referral rate of 28% (254/
913), a mean cluster size amongst the referred sample of
1.06 (254 lesions from 239 participants), and that 55% of
the referred lesions were assessed by the dermatology
experts to be 'clinically significant' in the combined arm
data. In this context of a higher rate of biopsy or monitor-
ing, the clinically worthwhile difference was altered to a
15% difference (an odds ratio of 1.8) from 45% to 60%. A
target total of 400 referred lesions from approximately
380 patients would provide 80% power to detect this dif-
ference at the 5% level of significance, and would require
an estimated 1450 study lesions from 1150 randomised
participants.
2.11 Analysis
Primary outcome (PPV of referral)
Analysis will be by intention-to-treat using the referred
population for the primary outcome (i.e. all lesions
referred to secondary care). The proportion of all referred
lesions that are deemed 'clinically significant' will be com-
pared between randomised groups using Donner's test
for clustered proportions via a linear mixed effects model
with patient as a random term. A secondary analysis
comparing the proportions (chi-squared test) without
allowance for clustering will enable an assessment as to
whether clustering makes any difference to the results. If
there is no material difference the simple analysis without
need of accounting for clustering will be reported.
Secondary outcomes
1. Related to the primary outcome 1.1 Volume effects
The volume of referrals will be measured by the per-
centage of randomised participants over the study period
who are referred by Lead Clinicians to secondary care,
and compared between randomised groups as a differ-
ence in proportions with 95% confidence interval for the
difference, and using the chi-squared test.
1.2 Sensitivity, specificity and negative predictive
value of the decision not to refer
Sensitivity, specificity and other study proportions of
lesions will be analysed using the same approach as for
the primary outcome measure. These data will be used to
compare the PPV of a referral (the primary outcome), and
the NPV (correct management of lesions not referred)
which will provide important data around lesions which
are incorrectly identified as not suspicious in general
practice. These data can contribute to further develop-
ment of the diagnostic algorithm embedded in the Mole-
Mate system.
2. Clinical outcomes Histological diagnosis of mela-
noma will be summarised as a rate in each randomised
group, with the denominator being the participants in
each randomised group: exact methods (95% confidence
interval and Fishers exact test) will be used to estimate
the difference in rates of melanoma. Melanoma thickness
(Breslow data) and other histological diagnoses will be
summarised using the same approach.
From five-year Cancer Registry follow-up for all partic-
ipants (incidence and mortality) survival analysis meth-
ods will be used, including the log rank test, Kaplan MeierWalter et al. BMC Family Practice 2010, 11:36
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survival plots, and Cox regression to estimate interven-
tion effects with 95% confidence intervals and associated
p-value (involving the full participant sample in each ran-
domised group (referred plus non-referred) to assess
overall effect of the introduction of the MoleMate system
compared to current best practice).
3. Clinician outcomes Continuous outcomes at the level
of clinician such as confidence and attitudes, and change
in these, towards the MoleMate system will be sum-
marised using a mean score and 95% confidence interval
and reporting the proportion of clinicians above a thresh-
old of adequate confidence.
Assessment for learning effects will be undertaken
using randomised comparisons of differences in propor-
tions across 'naive' and 'potentially contaminated' peri-
ods: if there is an improvement in performance in the
comparison arm and the intervention effect size becomes
smaller through Lead Clinicians' sequence of lesions
assessed, and this is a systematic effect established across
the study clinicians, this would be evidence of either a
learning effect or more general contamination.
The diagnostic performance of the seven-point check-
list and the Index of Suspicion scale will be assessed and
compared between the intervention and comparison
groups.
4. Patient outcomes Continuous secondary outcomes at
the participant level, such as anxiety, cancer worry, and
satisfaction with the consultation will be compared using
a t-test, assuming no clustering effects are identified.
Analyses will be unadjusted cross-sectional comparisons
between groups. Change over time will also be sum-
marised, reporting means at baseline and mean changes
between time-points.
5. Economic assessment The economic evaluation will
be a cost-utility analysis conducted from the perspective
of the UK National Health Service, assessing the incre-
mental quality adjusted life years (QALYs) gained and
incremental cost to the NHS from the MoleMate system
versus current best practice. The incremental cost-effec-
tiveness ratio will be calculated, and appropriate analysis
of uncertainty will be undertaken. Drawing on the trial
and other epidemiological and cost data from the litera-
ture, the analysis will be conducted over a 10 year time
horizon, and based on a decision tree, defined at the
point of analysis.
2.12 Trial organisation and management
A Trial Steering Committee, consisting of investigators,
research team members, expert dermatologists and plas-
tic surgeons, a statistician, a health economist, Biocom-
patibles plc (previously Astron Clinica) staff, two lay
members and an independent chair, has been formed and
will meet annually for the duration of the trial.
Discussion
This trial is designed to estimate the effect of the Mole-
Mate intervention, compared with current best practice,
on the management of suspicious pigmented lesions in
general practice, as reflected in the appropriateness
(PPV) of referrals to a skin cancer clinic. As such, we are
considering the MoleMate system as a diagnostic tool
and testing its effectiveness in the hands of primary care
clinicians. There has been increasing interest in clinical
decision support (CDS) aids in recent years, and they
range from electronic texts, drug information and prac-
tice guideline databases to rules-based guidance systems
that direct clinicians about exactly what to do for specific
clinical problems. The MoleMate system is a good exam-
ple of a CDS aid, with the incorporation of an algorithm
specifically developed for use in primary care, with a new
imaging technology already increasingly used by derma-
tologists. The MoleMate system has been developed to
extend the utility of SIAscopy from differentiating mela-
noma from other pigmented lesions in the secondary care
setting, to differentiating 'suspicious lesions' from 'non
suspicious lesions' in the primary care setting.
The trial seeks to address a common challenge for pri-
mary care health professionals- how to recognise and
appropriately manage the rarely-presenting but serious
conditions from commonly-presenting benign condi-
tions. Differentiating melanomas from other pigmented
lesions in primary care is particularly challenging, even
among men aged over 60 years more than 99.7% are esti-
mated to remain benign [6], and 95% of all lesions cur-
rently referred to a specialist prove to be benign [10]. The
development and rigorous evaluation of tools such as the
M o l e M a t e  s y s t e m  t o  a s s i s t  c l i n i c a l  d e c i s i o n  m a k i n g  i n
primary care is one approach to maximising referral effi-
ciency, and as such meets one objective of the National
Awareness and Early Diagnosis Initiative [5].
The measures and interventions for the MoleMate UK
Trial have been developed using the approach defined by
the MRC Framework for development of complex inter-
ventions for evaluation in randomised trials [27,28] to
ensure rigour, transparency and reproducibility. The
four-month pilot phase confirmed the proposed recruit-
ment and referral rates and the feasibility of participant
randomisation. It demonstrated the feasibility of tracking
referred participants in secondary care, and established
mechanisms for reference standard diagnosis for all
lesions recruited into the trial. During the pilot phase
semi-structured interviews and questionnaires con-
firmed that both participants and lead clinicians found all
aspects of the trial process, including randomisation,
were acceptable and did not appear to cause distress.
However, we await data from the main trial on the psy-
chological impact of trial participation and acceptability
of the MoleMate system.Walter et al. BMC Family Practice 2010, 11:36
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This trial tests a novel service model of internal referral
in general practice to Lead Clinicians who do not have
dermatological training. We are conducting an economic
evaluation of the use of the MoleMate system within this
service model to establish its cost-utility compared with
current best practice.
Our primary outcome measure is based on the clinical
significance of a lesion, as determined by the actual man-
agement (biopsy or monitor) by a skin cancer specialist.
This is a meaningful outcome in terms of health service
delivery and the need to improve referral efficiency.
While ideally we would have detection of melanoma as
the primary outcome, this would require a much larger
trial to have sufficient statistical power. We will capture
data on melanoma incidence and mortality in all partici-
pants over 5 years. This will provide important data on
the false negatives; lesions incorrectly diagnosed as
benign.
Conclusions
In conclusion, this is the first randomised controlled trial
in general practice of a decision aid using SIAscopy for
the assessment of pigmented skin lesions. Preliminary
data from diagnostic validation studies in the UK and
Australia suggest the MoleMate system is reasonably sen-
sitive and specific but only an RCT can determine its
effect on clinical management in the UK setting. If the
trial demonstrates that using the MoleMate system
improves diagnostic efficiency, it will add to the range of
approaches to support assessment of pigmented skin
lesions in UK primary care. If the trial provides evidence
of cost-utility it will inform new service models to reduce
referrals to secondary care of benign lesions and improve
the early diagnosis of melanoma.
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